RDDT, provides proprietary preclinical services, offering integrated service in different disease areas to the biotechnology and pharmaceutical industries. RDDT is a Global GLP compliant CRO

Building leading CRO for testing anti-cancer drugs in specialised tumour models

RDDT is now fully owned by vivoPharm, a global company providing integrated preclinical service to GLP compliance for safety and bioanalytical testing. RDDT is based in Melbourne, Australia.The integration of vivoPharm’s experience and global market position into the RDDT’s operations and strategies extents RDDT’s service portfolia immensilySince being awarded its GLP compliance status in 2004, RDDT is equipped to execute abroad range of toxicology studies (including genotoxicity, acute to chronic repeat dose studies etc) in various mammalian species in accordance to the appropriate regulatory standards. In addition, custom efficacy studies can be validated and performed to meet your needs. vivoPharm/RDDT partner with MPI Research in Michigan to provide services in monkeys, dogs and non-mammalian species.RDDT ensures excellent regulatory compliance based on OECD Guidelines in order to deliver the highest quality data to assist clients with their FDA, EMEA, TGA and other regulatory submissions. RDDT Laboratories’ quality system adheres to OECD Guidelines and US FDA 21CFR Part 58 GLP requirements.

Expanding vivoPharm's services to North America

New assay development in the field of cancer and angiogenesis

Development of new predictive animal tumur models, lead tumour biology project, developed AIDAM a special software for animal experimentation

Generation of transgenic tumour models for cancer research

Characterisation of a high molecular form of the Mammary-dervice growth inhibitor

Purification and characterization of growth inhibitors, in particular MDGI a member of the fatty acid binding proteins